Vivia’s innovative research model consists of analyzing the effect of thousands of existing drugs directly on a patient’s standard biological sample, for example blood or bone marrow.

Vivia is the worldwide pioneer in screening and profiling thousands of drugs on patients’ blood samples, an innovative Systems Biology Research model. This research is truly “translational”, and is enabled for the first time ever in the world by our ExviTech© Technology Platform.

In the first application of this technology within the scope of hematologic cancers (leukemia, lymphoma and multiple myeloma), this capacity has been used to measure the efficacy of drugs with regard to the selective elimination of cancer cells on the patient’s sample.